SCHEMBL2001471

SCHEMBL2001471

CC(C)c1ccc(Nc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
CYP26A1 O43174 1/20 0.58
MLKL Q8NB16 1/20 0.55
PDE10A Q9Y233 2/20 0.53
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ALOX15 P16050 2/20 0.50
GAA P10253 1/20 0.50
FFAR2 O15552 1/20 0.50
TP53 P04637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
DDX3X O00571 1/20 0.50
HPGD P15428 1/20 0.50
AKR1C3 P42330 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774292 0.84 MEN1 (0.57) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL13058945 0.84 MEN1 (0.57) MEN1KMT2ACYP26A1MLKLPDE10A
SCHEMBL20685416 0.83 MEN1 (1.00) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL1163897 0.83 MEN1 (0.71) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL6037544 0.83 MEN1 (0.71) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL13002096 0.83 MEN1 (0.56) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL30020996 0.82 MEN1 (0.75) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL239690 0.82 MEN1 (0.75) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL20685263 0.81 NPC1 (0.64) MEN1KMT2ACYP26A1PDE10ANPC1
SCHEMBL20685494 0.80 MEN1 (0.46) MEN1KMT2ACYP26A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US claimed
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US disclosed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US disclosed
EP-1896427-A2 NOVEL 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NeuroSearch A/S (DK) 2008-03-12 EP disclosed
WO-2006136580-A2 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels KCNN2, KCNN1, KCNN3 MEN1 2186/4885KMT2A 1406/4885CYP26A1 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.